New Anti-VEGF Agent Brolucizumab Shows Promise for AMD

According to new research, brolucizumab, a new anti-VEGF for neovascular AMD, is noninferior to aflibercept and may offer longer dosing intervals.
Medscape Ophthalmology

Full Story →